PEG IFN: Phase III started

Biogen Idec began the 2-year, double-blind, placebo-controlled, international Phase III ADVANCE trial to evaluate 125 µg of subcutaneous PEG IFN given once every 2 or 4 weeks in more than 1,200 patien...